KP405 Phase 1 PD trial (NCT06189170)

KP405 Phase 1 Parkinson's Disease Trial (NCT06189170)

Overview

Study Title: KP405 First-in-Human Study in Parkinson's Disease Intervention: KP405 (alpha-synuclein aggregation inhibitor) Company: Kariya Pharmaceuticals Phase: Phase 1 Status: Recruiting Clinicaltrials.gov ID: NCT06189170

Therapeutic Context

The Need for Disease-Modifying Therapies in Parkinson's Disease

KP405 Phase 1 Parkinson's Disease Trial (NCT06189170)

Overview

Study Title: KP405 First-in-Human Study in Parkinson's Disease Intervention: KP405 (alpha-synuclein aggregation inhibitor) Company: Kariya Pharmaceuticals Phase: Phase 1 Status: Recruiting Clinicaltrials.gov ID: NCT06189170

Therapeutic Context

The Need for Disease-Modifying Therapies in Parkinson's Disease

Parkinson's disease (PD) is the second most common neurodegenerative disorder after [Alzheimer's disease](/diseases/alzheimers-disease), affecting approximately 6 million people worldwide. [@parkinsons2020] Current treatments provide only symptomatic relief and do not address the underlying disease progression. There is a critical unmet need for disease-modifying therapies that can slow or halt the neurodegenerative process.

The pathological hallmark of PD is the presence of Lewy bodies—intracellular inclusions composed primarily of aggregated [alpha-synuclein](/proteins/alpha-synuclein) (α-syn) protein—along with the progressive loss of dopaminergic [neurons](/cell-types/dopaminergic-neurons) in the substantia nigra pars compacta. [@baba1998; @spillantini1998] This understanding has driven significant research into therapeutic strategies targeting α-syn aggregation.

Alpha-Synuclein Aggregation as a Therapeutic Target

Alpha-synuclein is a 140-amino acid protein encoded by the [SNCA](/genes/snca) gene, predominantly expressed in presynaptic terminals of [neurons](/cell-types/neurons). [@pagan2019] In PD, α-syn undergoes a toxic transformation:

The aggregation of α-syn is thought to be a central pathological event driving neuronal dysfunction and death. [@volc2020] Genetic evidence supports this hypothesis:

• [SNCA](/genes/snca) gene multiplications cause familial PD [@singleton2017]
• Mutations (A53T, A30P, E46K) increase aggregation propensity
• [GBA](/genes/gba) mutations increase risk for PD with more rapid progression

Current Therapeutic Approaches

Current therapeutic approaches targeting α-syn aggregation include: [@athauda2017; @levin2019]

• Small Molecule Inhibitors: Compounds that prevent nucleation and fibril formation (e.g., Anle138b, KP405)
• Antisense Oligonucleotides: Gene therapy approaches to reduce SNCA expression
• Immunotherapies: Active and passive vaccines targeting α-syn
• Autophagy Enhancers: Compounds that promote clearance of aggregated α-syn (e.g., nilotinib, rapamycin)

KP405 Drug Profile

Mechanism of Action

KP405 is a small molecule alpha-synuclein aggregation inhibitor designed to: [@ Pujols2018]

• Directly bind to α-synuclein monomers and prevent conformational change
• Inhibit oligomerization by blocking the nucleation process
• Prevent fibril formation by stabilizing the non-aggregated state
• Target the NACore (residues 61-95) — the central aggregation domain

Molecular Design Rationale

Unlike earlier aggregation inhibitors that focused on post-aggregation effects, KP405 is designed to act at the earliest possible step in the aggregation cascade—preventing the initial conformational transition from monomer to oligomer. This approach may be more effective in early-stage disease where significant neuronal loss has not yet occurred. [@kim2019]

The compound's design prioritizes:

• Blood-brain barrier penetration for central nervous system activity
• Selectivity for α-syn over other amyloidogenic proteins
• Optimized pharmacokinetics for chronic dosing
• Safety profile suitable for long-term treatment

Preclinical Evidence

Preclinical studies of KP405 demonstrate:

• Dose-dependent reduction in α-syn aggregation in cell models
• Protection against α-syn-induced neurotoxicity
• Favorable pharmacokinetic properties
• Good tolerability in animal models

Clinical Development

Study Design

NCT06189170 is a first-in-human study designed to evaluate the safety, tolerability, and pharmacokinetics of KP405 in patients with Parkinson's disease.

• Study Type: First-in-human (FIH) study
• Design: Single ascending dose (SAD) followed by multiple ascending dose (MAD)
• Population: Patients with confirmed Parkinson's disease
• Primary Endpoints: Safety and tolerability
• Secondary Endpoints: Pharmacokinetic parameters, biomarker assessments

Rationale for Early-Phase Design

Phase 1 trials in neurodegenerative disease present unique challenges: [@prinz2013]

• Need to establish safety in the target patient population
• Require understanding of CNS exposure and target engagement
• Need to identify optimal dosing for later-phase trials
• Must balance early efficacy signals with safety

Biomarker Assessments

The trial includes biomarker assessments to evaluate target engagement: [@devoto2021]

• CSF α-synuclein species: Total, oligomeric, and phosphorylated forms
• Neurofilament light chain (NfL): Marker of neuronal damage
• α-syn RT-QuIC: Seed amplification assay for pathological α-syn

Clinical Context: Alpha-Synuclein Aggregation Inhibitors in Development

Comparison with Other Candidates

| Compound | Company | Mechanism | Phase | Status |
|----------|---------|-----------|-------|--------|
| KP405 | Kariya Pharmaceuticals | Small molecule inhibitor | Phase 1 | Recruiting |
| Anle138b | MODAG | Small molecule inhibitor | Phase 1 | Completed |
| UBL-0401 | UCB Pharma | Small molecule inhibitor | Phase 1 | Completed |
| Prasinezumab | Roche/Prothena | Anti-α-syn antibody | Phase 2 | Active |
| Cinpanemab | Biogen | Anti-α-syn antibody | Phase 2 | Terminated |

Anle138b

Anle138b (also known as "AP-234") is a small molecule aggregation inhibitor that has completed Phase 1 clinical testing. [@levin2019] It works by directly binding to α-syn and preventing oligomerization and fibril formation. Preclinical studies showed rescue of dopaminergic neurons in PD models.

Immunotherapy Approaches

Passive immunotherapy targeting α-syn has been explored extensively: [@volc2020]

• Prasinezumab (PRX002): Antibody targeting α-syn oligomers; Phase 2 showed signals of efficacy
• Cinpanemab (BIIB054): Antibody targeting α-syn fibrils; Phase 2 did not meet primary endpoints
• MEDI1341: Antibody targeting α-syn; Phase 1 completed

Autophagy Enhancers

An alternative approach involves enhancing cellular clearance mechanisms:

• Nilotinib: BCR-ABL inhibitor that induces autophagy; Phase 2 showed biological activity signals
• Rapamycin: mTOR inhibitor; evaluated for neurodegenerative disease

Disease Background

Parkinson's Disease Pathology

[Parkinson's disease](/diseases/parkinsons-disease) is characterized by:

• Progressive loss of dopaminergic neurons in substantia nigra
• Presence of Lewy bodies (α-syn aggregates)
• Motor symptoms: tremor, bradykinesia, rigidity, postural instability
• Non-motor symptoms: sleep disorders, autonomic dysfunction, cognitive decline

Progression and Therapeutic Window

The preclinical and prodromal phases of PD may represent the optimal therapeutic window, before significant neuronal loss has occurred. [@angelova2020] This underscores the importance of:

• Early diagnosis using biomarkers
• Disease-modifying therapies that can be initiated before substantial neurodegeneration
• Patient selection based on biomarker profiles

Study Protocol Details

Inclusion Criteria (Expected)

• Confirmed diagnosis of Parkinson's disease
• Age 40-80 years
• Motor symptoms (Hoehn & Yahr stage 1-3)
• Stable PD medication for specified period
• Ability to provide informed consent

Exclusion Criteria (Expected)

• Atypical parkinsonism
• Significant cognitive impairment
• Psychiatric comorbidities
• Medical conditions precluding study participation

Outcome Measures

Primary Outcomes:

• Adverse events (AEs) and serious adverse events (SAEs)
• Laboratory parameters (hematology, chemistry, urinalysis)
• Vital signs and physical examination
• Electrocardiogram (ECG)

• Maximum tolerated dose (MTD)
• Pharmacokinetic parameters (Cmax, AUC, half-life)
• CSF biomarker changes

Future Development Plans

If Phase 1 is successful, KP405 would advance to:

• Phase 2: Dose-finding and preliminary efficacy
• Phase 3: Registration trials with disease progression endpoints

Regulatory Considerations

Alpha-synuclein aggregation inhibitors have received regulatory attention:

• FDA has granted fast-track designation to several candidates
• EMA has provided scientific advice on trial design
• Consensus guidelines on outcome measures for PD clinical trials

Conclusion

KP405 represents a promising disease-modifying therapeutic approach for Parkinson's disease by directly targeting the α-syn aggregation process that underlies dopaminergic neuron loss. The successful development of KP405 and similar agents could address the significant unmet need for therapies that slow or halt disease progression in PD.

See Also

• [Alpha-Synuclein Aggregation Inhibitors](/therapeutics/alpha-synuclein-aggregation-inhibitors)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Parkinson's Disease Mechanisms](/mechanisms/alpha-synuclein-pathology)
• [Alpha-Synuclein Propagation](/mechanisms/alpha-synuclein-propagation)
• [Lewy Body Disease](/diseases/dementia-with-lewy-bodies)

External Links

• [ClinicalTrials.gov: NCT06189170](https://clinicaltrials.gov/study/NCT06189170)
• [Alpha-Synuclein Aggregation Inhibitors Clinical Trials](https://clinicaltrials.gov/search?cond=Parkinson+disease&intr=alpha-synuclein+aggregation+inhibitor)
• [Small Molecule Inhibitors - PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=alpha-synuclein+aggregation+inhibitor+small+molecule)

References